Immune checkpoint inhibition (ICI) targeting the programmed cell death protein 1 (PD-1), programmed cell death protein ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has dramatically improved outcomes in melanoma patients [1,2]. The gene discussed is CTLA4; the disease is melanoma.